These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26241951)

  • 1. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
    Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
    Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
    Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
    J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems.
    Kalariya M; Amiji MM
    Int J Pharm; 2013 Sep; 453(2):400-7. PubMed ID: 23702000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
    Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
    Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
    Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
    J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on effect of lentinan in enhancing anti-tumor action of dendritic cytoma vaccine and its mechanism].
    Wang J; Zhou ZD; Xia DJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jan; 27(1):60-4. PubMed ID: 17302067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo.
    Elzaouk L; Pavlovic J; Moelling K
    Hum Gene Ther; 2006 Aug; 17(8):859-70. PubMed ID: 16942445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.
    Rakhmilevich AL; Imboden M; Hao Z; Macklin MD; Roberts T; Wright KM; Albertini MR; Yang NS; Sondel PM
    Clin Cancer Res; 2001 Apr; 7(4):952-61. PubMed ID: 11309346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-transfection gene delivery of dendritic cells induced effective lymph node targeting and anti-tumor vaccination.
    Chen YZ; Ruan GX; Yao XL; Li LM; Hu Y; Tabata Y; Gao JQ
    Pharm Res; 2013 Jun; 30(6):1502-12. PubMed ID: 23371516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.
    Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J
    Tumori; 2015; 101(6):637-43. PubMed ID: 25983089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
    Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
    Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
    Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
    Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.
    Soong RS; Song L; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
    PLoS One; 2014; 9(3):e93162. PubMed ID: 24664420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.